Detalles de la búsqueda
1.
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
Br J Cancer;
130(11): 1783-1794, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38519705
2.
Tracheomediastinal fistula induced by concurrent chemoradiotherapy in small cell lung cancer: A case report and literature review.
Thorac Cancer;
15(13): 1106-1111, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38528720
3.
Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations.
Respir Investig;
62(3): 334-338, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38412569
4.
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma.
JTO Clin Res Rep;
5(1): 100613, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38229769
5.
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Clin Cancer Res;
30(6): 1104-1110, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38165684
6.
Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
J Thorac Oncol;
19(2): 337-343, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37943237
7.
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
JAMA Oncol;
10(3): 315-324, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38127362
8.
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
JAMA Oncol;
9(11): 1505-1513, 2023 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676681
9.
Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum-based chemotherapy.
Thorac Cancer;
14(22): 2225-2228, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37337950
10.
Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors.
Lung Cancer;
181: 107264, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37276707
11.
Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patients.
Cancer Med;
12(13): 14327-14336, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37211905
12.
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer.
Sci Rep;
13(1): 3698, 2023 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36878936
13.
Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer.
Cancer Med;
12(6): 7090-7104, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36621830
14.
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.
Transl Lung Cancer Res;
11(11): 2208-2215, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36519019
15.
Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases.
Cancer Manag Res;
14: 3449-3453, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36540201
16.
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.
BMC Cancer;
22(1): 964, 2022 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36076179
17.
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Clin Cancer Res;
28(20): 4402-4409, 2022 10 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35980349
18.
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L).
Clin Cancer Res;
: OF1-OF7, 2022 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762926
19.
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE).
Oncol Ther;
10(1): 253-262, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35246827
20.
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Cancer Sci;
113(1): 221-228, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34704312